Skin Cancer

Multicenter melanoma vaccine study demonstrates promising results

Published in Drug Week, July 2nd, 2004

Results from the largest multisite study conducted to date, evaluating a peptide-derived therapeutic vaccine for melanoma, were released by the Eastern Cooperative Oncology Group (ECOG) at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) in New Orleans.

The findings provide promising evidence that researchers can activate a patient's own immune system to fight advanced melanoma.

"This is the first time we have evaluated peptide-derived melanoma vaccine results from a multicenter cooperative group trial," said John Kirkwood, MD, principal investigator of the study, professor of medicine at the University of Pittsburgh and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry